Pharmaust Ltd represents values of innovation, integrity, and commitment to improving healthcare. The company prides itself on developing novel therapies to address unmet medical needs. Pharmaust is dedicated to advancing the field of oncology through cutting-edge research and development. They strive to bring effective and safe treatments to patients worldwide. With a focus on collaboration and excellence, Pharmaust is driven by a corporate philosophy centered around improving patient outcomes and enhancing quality of life. Through their dedication to scientific advancement and patient-centric approach, Pharmaust Ltd aims to make a significant impact in the pharmaceutical industry.

Pharmaust Ltd is primarily present in Australia and New Zealand.

Pharmaust Ltd has achieved several significant milestones. One of the notable achievements is the development and successful testing of their lead drug candidate, monepantel (known as MP-10), which has shown promising results in treating various types of cancers including prostate, pancreatic, and ovarian cancer. The company has also received regulatory approvals for clinical trials and has been granted patents for its innovative drug delivery technology. Additionally, Pharmaust Ltd has entered into important research collaborations and partnerships to further advance their drug development programs.Overall, Pharmaust Ltd has made remarkable strides in the field of cancer research and drug development.

Pharmaust Ltd, a leading pharmaceutical company, has a rich history and background that highlights its growth and success. Established in [year], Pharmaust Ltd has cemented its position as a reputable player in the industry. With a focus on innovation and cutting-edge research, the company has consistently achieved significant milestones, such as the development of ground-breaking drugs and successful clinical trials. Pharmaust Ltd's commitment to improving healthcare outcomes showcases its dedication to enhancing the quality of life for patients worldwide. With a strong emphasis on research and development, Pharmaust Ltd continues to push boundaries in the pharmaceutical sector, making it a key player in the market.

The main competitors of Pharmaust Ltd in the market include various pharmaceutical companies and biotechnology firms operating in the same sector. It is important to note that competition varies depending on the specific products and services offered by Pharmaust Ltd, as well as their geographical presence. However, some notable competitors in the industry include pharmaceutical giants such as Pfizer, Johnson & Johnson, and Novartis, as well as biotech companies like Amgen and Gilead Sciences. These competitors also strive to develop innovative therapies and medications, contributing to a highly competitive landscape in the pharmaceutical market.

Pharmaust Ltd is primarily active in the pharmaceutical industry.

The business model of Pharmaust Ltd revolves around the research, development, and commercialization of novel pharmaceutical products. The company focuses on the discovery and advancement of innovative therapeutics to address critical unmet needs in the field of anticancer and antiviral treatments. Pharmaust Ltd employs a strategic approach, utilizing cutting-edge technologies and collaborations with leading research institutions to develop potential drug candidates. By progressing through preclinical and clinical trials, Pharmaust aims to ultimately introduce safe and effective drugs to market, benefiting patients worldwide. With its dedicated team and commitment to scientific excellence, Pharmaust Ltd aims to make significant advancements in the healthcare industry.

KGV za Pharmaust trenutno ne može biti izračunato.

KUV za Pharmaust trenutno ne može biti izračunat.

AlleAktien kvalitativni skor za Pharmaust je 5/10.

Prihod trenutno ne može biti izračunat za Pharmaust.

Profit trenutno ne može biti izračunat za Pharmaust.

Pharmaust Ltd is an Australian biotechnology company that specializes in the research and development of novel immunotherapies for cancer and other chronic diseases. The company's main focus is on discovering new compounds and manufacturing drugs that can activate the body's immune system to fight against cancer cells or serious chronic diseases. The business model of Pharmaust Ltd is based on conducting innovative research projects and developing new therapeutics. The company focuses on researching new biological compounds with the goal of developing a wide range of new drugs that can improve the effectiveness and tolerability of existing cancer therapies. Pharmaust operates three main business areas: 1. Research & Development: The company has an experienced research team that identifies new compounds and investigates their effectiveness and safety. The goal is to develop new therapeutics that can activate the immune system against cancer cells. 2. Licensing: Pharmaust aims to license its technologies and therapeutics worldwide. The company collaborates with various partners and academic institutions to spread the benefits of its products globally. 3. Commercial Research: Pharmaust also conducts commercial research projects that aim to improve the effectiveness and safety of existing therapeutics and identify new applications for them. Pharmaust also offers a range of products, including: 1. Monepantel: Monepantel is a novel antiparasitic used to combat gastrointestinal worms in sheep. It was developed by Pharmaust Ltd in collaboration with the Commonwealth Scientific and Industrial Research Organisation (CSIRO). 2. PPL-1C: PPL-1C is a novel compound that activates the immune system to fight against cancer cells. The drug is currently being tested in clinical trials. Pharmaust has successfully implemented various approaches to develop new immuno-oncology therapeutics. The focus is on developing antibodies or small molecules that activate the immune system and stimulate natural T-cells to target cancer cells. In summary, Pharmaust Ltd is an innovative biotechnology company specializing in the development of immunotherapies against cancer and other chronic diseases. With an experienced research team and a variety of products in its portfolio, Pharmaust strives to contribute to improving the quality of life for millions of people worldwide.

Pharmaust isplaćuje dividendu od 0 AUD raspoređenu preko isplata u toku godine.

Dividenda za Pharmaust trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Pharmaust je AU000000PAA1.

WKN od Pharmaust je A0DNJ3.

Oznaka za praćenje akcija kompanije Pharmaust je PAA.AX.

U poslednjih 12 meseci, Pharmaust je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Pharmaust će verovatno isplatiti dividendu od 0 AUD.

Dividendski prinos od Pharmaust trenutno iznosi .

Pharmaust isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Pharmaust je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 AUD. To odgovara dividendnom prinosu od 0 %.

Pharmaust se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Pharmaust od 9. 8. 2024. u iznosu od 0 AUD, morali ste da imate akciju u depou pre Ex-dana 9. 8. 2024..

Isplata poslednje dividende izvršena je 9. 8. 2024..

U godini 2023 kompanija Pharmaust je isplatila 0 AUD kao dividende.

Dividende od Pharmaust se isplaćuju u AUD.